|
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
NOT_RECRUITINGPhase 2Sponsored by Sung-Hwan Kim
No longer actively recruiting
PhasePhase 2
SponsorSung-Hwan Kim
Started2022-05-20
Est. completion2024-05-20
Eligibility
Age19 Years – 79 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05540587
Summary
This study aims to compare the efficacy and safety of the edoxaban and the warfarin in atrial fibrillation patients with mitral stenosis. The study design is a multicenter, randomized, open-label, investigator initiated phase 2 trial. The patients were randomly assigned to Edoxaban or Warfarin groups. Primary outcome was a composite of stroke and systemic arterial thromboembolism. The safety outcome was major bleeding.
Eligibility
Age: 19 Years – 79 YearsHealthy volunteers accepted
* Inclusion criteria
* 18 \< Age \< 80
* AF diagnosed by ECG at any time prior to enrollment
* Moderate or severe mitral valve stenosis diagnosed by echocardiography at any time prior to enrollment
* Exclusion criteria
* Refusal to consent
* Transient AF due to reversible cause (Postoperative, ongoing systemic inflammation, thyrotoxicosis)
* Patients undergoing mechanical valve replacement
* Coagulopathy
* Hepatic impairment with significant bleeding risk
* High bleeding risk due to following disease or condition diagnosed within 1 month prior to randomization
* GI ulcer or bleeding, Esophageal or gastric varix, Malignancy, Brain or cord injury, Surgery for brain, spinal cord, opthalmic, Intracranial hemorrhage, Arteriovenous malformation, Vascular aneurysms, Brain or spinal vascular disorder
* Stroke, Systemic arterial thromboembolism, Acute myocardial infarction diagnosed within 14 days prior to randomization
* End stage kidney disease (CrCL \< 15mL/min) or Dialysis
* Severe hypertension
* Alcohol abuse or other psychiatric disease
* Epidural puncture or anesthesia
* Pulmonary thromboembolism with hemodynamical instability requiring thrombolysis or thrombectomy
* Pregnant or lactating women
* Allergy to edoxaban or warfarin
* Ongoing need for other anticoagulant or clarithromycin, rifampin)
* Participants for other trials within 1 month prior to enrollment
* Other patients to be inappropriate to participate in the trial determined by the investigatorConditions5
Atrial FibrillationHeart DiseaseMitral Valve StenosisStrokeSystemic Embolism
Interventions2
Related trials
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation — Oslo University Hospital
- Anticoagulation in Post MI LV Thrombus Trial in Nepal — Shahid Gangalal National Heart Centre
- Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease — Children's Hospital of Fudan University
- The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis — Nicholas Carlson
- Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device — Columbia University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 2
SponsorSung-Hwan Kim
Started2022-05-20
Est. completion2024-05-20
Eligibility
Age19 Years – 79 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05540587